Poor cell viability after transplantation has restricted the therapeutic capacity of mesenchymal stem cells (MSCs) for cardiac dysfunction after myocardial infarction (MI). Growth arrest-specific gene 6 (Gas6) encodes a secreted γ-carboxyglutamic acid (Gla)-containing protein that functions in cell growth， adhesion， chemotaxis， mitogenesis and cell survival. In this study， we genetically modified MSCs with Gas6 and evaluated cell survival， cardiac function， and infarct size in a rat model of MI via intramyocardial delivery. Functional studies demonstrated that Gas6 transfer significantly reduced MSC apoptosis， increased survival of MSCs in vitro and in vivo， and that Gas6-engineered MSCs (MSC)-treated animals had smaller infarct size and showed remarkably functional recovery as compared with control MSCs (MSC)-treated animals. Mechanistically， Gas6 could enhance phosphatidylinositol 3-kinase (PI3K)/Akt signaling and improve hypoxia-inducible factor-1 alpha (HIF-1α)-driven secretion of four major growth factors (VEGF， bFGF， SDF and IGF-1) in MSCs under hypoxia in an Axl-dependent autocrine manner. The paracrine action of MSC was further validated by coculture neonatal rat cardiomyocytes with conditioned medium from hypoxia-treated MSC， as well as by pretreatment cardiomyocytes with the specific receptor inhibitors of VEGF， bFGF， SDF and IGF-1. Collectively， our data suggest that Gas6 may advance the efficacy of MSC therapy for post-infarcted heart failure via enhanced Gas6/Axl autocrine prosurvival signaling and paracrine cytoprotective action.